Skip to content
HowShorted

Sana Biotechnology, Inc. short interest in 2025

In 2025, Sana Biotechnology, Inc.'s disclosed short interest ran from 22.52% of shares outstanding on 15 Jan 2025 to 13.75% on 31 Dec 2025, a change of -8.77 percentage points. The year's high was 22.52% on 15 Jan 2025 and its low 12.01% on 31 Oct 2025, averaging 16.19% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 21.06 days on 30 Apr 2025. Full history: Sana Biotechnology, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Sana Biotechnology, Inc. in 2025

2025 in figures

Start of year
22.52% (15 Jan 2025)
End of year
13.75% (31 Dec 2025)
Change
-8.77 pp
High
22.52% (15 Jan 2025)
Low
12.01% (31 Oct 2025)
Average
16.19%
Highest days to cover
21.06 (30 Apr 2025)
SEC filings marked
9

Every report in 2025

Sana Biotechnology, Inc. short interest in 2025
SettlementShort interestDays to coverFilings since previous
15 Jan 202522.52%1.77
31 Jan 202520.20%6.81
14 Feb 202519.86%14.73
28 Feb 202518.81%17.11
14 Mar 202517.73%15.25
31 Mar 202517.89%8.6810-K filed, results (8-K)
15 Apr 202518.05%8.07
30 Apr 202517.81%21.06
15 May 202518.37%12.6610-Q filed, results (8-K)
30 May 202519.67%10.07
13 Jun 202519.36%12.46
30 Jun 202516.68%6.11
15 Jul 202515.49%4.92
31 Jul 202513.68%6.56
15 Aug 202514.03%4.50results (8-K), 10-Q filed, results (8-K)
29 Aug 202512.70%6.51
15 Sep 202512.12%8.13
30 Sep 202514.05%8.73
15 Oct 202512.87%4.66
31 Oct 202512.01%5.28
14 Nov 202512.43%8.3510-Q filed, results (8-K)
28 Nov 202514.39%8.94
15 Dec 202514.18%6.11
31 Dec 202513.75%9.86

See also: Sana Biotechnology, Inc.'s full history · most shorted US stocks of 2025 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.